US FDA refuses to accept Theravance's re-submission of Vibativ for hospital-acquired pneumonia
This article was originally published in Scrip
Executive Summary
The US FDA has dealt a major blow to Theravance's quest to gain a supplemental hospital-acquired pneumonia (HAP) indication for its injectable broad-spectrum antibiotic Vibativ (telavancin) by refusing to accept two Phase III studies that are supporting the sNDA as separate entities, since their primary endpoint data were pooled together.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.